Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 2, 2013, Pages 231-237

  Huang, Pauline Y ^a   Kohnke, Philippa ^a   Belov, Larissa ^a   Best, O Giles ^a   Mulligan, Stephen P ^b   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR;

ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; ANTIGENS, CD; DISEASE PROGRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROARRAY ANALYSIS;

EID: 84890238782     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3f01c     Document Type: Article

References (12)

1. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle RN, Wasil T, Rai KR, Hellerstein MK, Chiorazzi N. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest, 2005; 115:755-64.
2. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia, Blood, 2012; 120:4684-4691.
3. Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion? Curr Hematol Malig Rep, 2011; 6:36-46.
4. Huang PY, Best OG, Belov L, Mulligan SP, Christopherson RI. Surface profiles for subclassification of chronic lymphocytic leukemia. Leuk Lymphoma, 2012; 53:1046-56.
5. Belov L, Mulligan SP, Barber N, Woolfson A, Scott M, Stoner K, Chrisp JS, Sewell WA, Bradstock KF, Bendall L, Pascovici DS, Thomas M, Erber W, Huang P, Sartor M, Young GA, Wiley JS, Juneja S, Wierda WG, Green AR, Keating MJ, Christopherson RI. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol, 2006; 135:184-97.
6. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 2008; 111:5446-56.
7. Belov L, Huang P, Barber N, Mulligan SP, Christopherson RI. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics, 2003; 3:2147-2154.
8. Matesanz-Isabel J, Sintes J, Llinàs L, de Salort J, Lázaro A, Engel P. New B-cell CD molecules. Immunol Lett, 2011; 134:104-12.
9. Hamelinck D, Zhou H, Li L, Verweij C, Dillon D, Feng Z, Costa J, Haab BB. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics, 2005; 4:773-784.
10. Sill M, Schroder C, Hoheisel JD, Benner A, Zucknick M. Assessment and optimisation of normalisation methods for dual-colour antibodymicroarrays. BMC Bioinformatics, 2010; 11:556.
11. Zola H, Swart B, Nicholson I, Voss E. Leukocyte and stromal cell molecules: The CD markers. John Wiley and Sons Inc. New Jersey, USA, 2007.
12. Johansson H, Albrekt AS, Borrebaeck CA, Lindstedt M. The GARD assay for assessment of chemical skin sensitizers. Toxicol In Vitro, 2013; 27:1163-9.